Collaboration Between Myriad Genetics and Gabbi Enhances Cancer Risk Tools
Collaboration to Enhance Hereditary Cancer Risk Assessments
In an exciting development for women’s health, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, has announced a collaboration with Gabbi, a telehealth solution focused on breast cancer risk assessment and specialist care services. Together, they aim to enhance the accessibility and effectiveness of hereditary cancer risk assessment tools.
Empowering Women through Comprehensive Care
Kaitlin Christine, the Founder and CEO of Gabbi, shared her personal motivation, stating, “After losing my mom to breast cancer and facing my own diagnosis, I am dedicated to helping women understand their cancer risks and access the necessary care.” This collaboration emphasizes the importance of genetic testing in assessing an individual's risk of developing breast cancer. Myriad's MyRisk with RiskScore Test offers clear, actionable insights, providing a solid foundation for personalized care plans.
Gabbi’s Telehealth Solution
Gabbi has developed a solution that streamlines breast cancer risk assessment by providing logistics and educational support to women. This includes connecting potentially at-risk patients with clinicians who can evaluate them for the MyRisk Hereditary Cancer Test, creating a seamless experience in their healthcare journey.
Significant Impact on Patient Care
The science behind the MyRisk with RiskScore is compelling; studies have shown that approximately 53% of patients qualify for changes in their medical management based on the results. This may lead to increased surveillance measures like more frequent mammograms or MRI imaging, which are critical for early cancer detection.
The Vision of Myriad Genetics
Melissa Gonzales, President of Myriad Women’s Health, stated, “Hereditary cancer risk assessment can provide peace of mind and facilitate access to early detection screening tools for those at higher risk for breast cancer.” The collaboration with Gabbi aligns perfectly with Myriad's core mission to empower women to understand and manage their breast cancer risks.
About Gabbi and Its Objectives
Gabbi plays a vital role in supporting thousands of women as they navigate the complexities of breast cancer risk assessment. Their team of clinical breast specialists is available to answer questions, develop tailored plans, and streamline the process of obtaining relevant imaging and tests. Gabbi's dedicated approach ensures that women receive timely care, maximizing their chances of early detection.
Myriad Genetics: A Leader in Molecular Diagnostics
Myriad Genetics is at the forefront of advancing healthcare through innovative molecular testing solutions. Their tests help assess disease risks and guide treatment decisions that enhance patient care across various medical specialties. By continuing to develop new techniques and tools, Myriad aims to lower healthcare costs while improving patient outcomes.
Frequently Asked Questions
What is the purpose of the collaboration between Myriad Genetics and Gabbi?
The collaboration aims to enhance access to hereditary cancer risk assessments and provide better support for women to understand their breast cancer risks.
How does Gabbi assist patients?
Gabbi offers telehealth services that include education, logistics support, and connections to clinicians for hereditary cancer risk evaluations.
What is the MyRisk with RiskScore Hereditary Cancer Test?
The MyRisk with RiskScore is a genetic test that provides actionable results, helping to personalize a care plan for women based on their cancer risk.
What support does Gabbi provide for patients who are at risk?
Gabbi connects patients with specialists who help them understand their risk and create tailored management plans, including ordering necessary imaging.
What are Myriad Genetics’ main goals?
Myriad Genetics aims to advance health and well-being through molecular testing that assesses disease risks and informs treatment decisions.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.